Related Experiment Video
Updated: Dec 31, 2025

10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.5K
Sorafenib for relapsed FLT3-ITD-positive acute myeloid leukemia postallogeneic stem cell transplantation presenting
Rachel Brodie1, Stephen E Langabeer2, John Quinn3
1Department of Haematology St. James's Hospital Dublin Ireland.
Clinical Case Reports
|January 2, 2020
Abstract:
Relapse of FLT3-mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.
Keywords:
FLT3 mutationacute myeloid leukemiaallogeneic stem cell transplantationleukemia cutisrelapsesorafenib
